In a significant move for the landscape of digital medicine, the U.S. Food and Drug Administration (FDA) has officially admitted Cadence—a leader in AI-enabled clinical software—into its prestigious Total Product Life Cycle Advisory Program (TEMPO) pilot. This inclusion marks a pivotal moment for chronic disease management, as the agency seeks to integrate real-world evidence from digital health technologies directly into the Medicare ecosystem. By leveraging Cadence’s specialized platform, the pilot aims to set a new gold standard for how hypertension is monitored, treated, and managed at scale.
Main Facts: A New Frontier for Digital Therapeutics
The TEMPO pilot is designed to foster a collaborative environment between regulators, technology developers, and healthcare providers. By participating in this program, Cadence is positioned to demonstrate how its proprietary software, HypertensionOS, can safely and effectively extend the reach of clinicians managing Stage 2 hypertension.
HypertensionOS is not a consumer-facing wellness app; it is a clinical-grade, prescription-only software system designed to augment the capabilities of physicians and advanced practice nurses. The platform automates the repetitive, time-intensive aspects of blood pressure management—namely the initiation and titration of antihypertensive medications—while maintaining strict adherence to physician-defined safety parameters and clinical guidelines.
The integration of Cadence into the TEMPO pilot is part of a broader, synchronized effort between the FDA and the Centers for Medicare and Medicaid Services (CMS). This dual-agency approach ensures that the digital tools vetted by the FDA can be seamlessly deployed to Medicare beneficiaries, bridging the gap between innovative software development and real-world clinical implementation.
Chronology: The Path to Digital Integration
The journey to this announcement has been marked by rigorous evidence-gathering and a shifting regulatory focus toward "software as a medical device" (SaMD).
- Initial Development: Cadence focused its early engineering efforts on building a platform that could reliably manage complex medication titration protocols without compromising patient safety. By focusing on Stage 2 hypertension, the company targeted a high-risk population that benefits significantly from proactive management.
- Evidence Validation: Over the past few years, the company conducted extensive retrospective analyses of its software’s performance. A landmark study involving over 23,000 patients demonstrated that HypertensionOS was associated with an average blood pressure reduction of 7/5 mm Hg after 30 weeks—a clinically significant improvement that correlates with lower risks of stroke and cardiovascular events.
- The CMS/FDA Synergy: Recognizing the potential for digital tools to curb the rising costs of chronic care, CMS launched a new innovation model focused on digital health. The FDA’s TEMPO program was established to provide the regulatory framework for these devices, ensuring they meet high safety and efficacy bars before widespread deployment.
- July 2026: Dexcom became the inaugural participant in the TEMPO program, signaling the FDA’s commitment to prioritizing metabolic and cardiovascular digital health tools.
- August 17, 2026: Cadence is formally announced as the latest participant in the TEMPO pilot, expanding the program’s footprint into hypertension management.
Supporting Data: Efficacy and Clinical Impact
The efficacy of AI in healthcare is often met with skepticism, but the data supporting Cadence’s HypertensionOS provides a compelling case for its utility. Hypertension is a leading driver of cardiovascular morbidity, yet millions of patients struggle to reach their target blood pressure due to infrequent clinic visits and the complexity of titration.
The retrospective analysis of 23,000 users serves as the bedrock of the company’s argument for inclusion in the TEMPO program. By automating the monitoring of blood pressure data and prompting dose adjustments within physician-approved boundaries, the software essentially creates a "virtual care team" that operates 24/7.
Crucially, the software is built with "guardrails." It is explicitly not designed for patients with high-acuity conditions—such as those with end-stage renal disease, active cancer, or pregnancy—where medication management requires specialized, real-time human intervention. By limiting the scope of the software to stable, high-risk populations, Cadence minimizes clinical risk while maximizing the efficiency of the primary care physician.
Official Responses: Defining the Future of Clinical AI
Industry leaders and regulators have framed this partnership as a turning point for the "clinical AI" movement.
"The opportunity for clinical AI is to extend the judgment and reach of clinicians by safely carrying out routine care within the boundaries they define," said Cadence CEO Chris Altchek in a statement following the announcement. "Our selection for TEMPO gives us the opportunity to help establish the evidence, safeguards, and operating model needed to bring that vision to millions of people living with chronic disease."
For the FDA, the TEMPO program represents a move away from static, point-in-time device approval toward a "total product life cycle" approach. In this model, the agency continuously monitors the performance of the software as it learns from real-world usage data. This is particularly important for AI-driven systems that may update their algorithms over time.
The FDA’s long-term goal is to fill the four pillars of its current focus: early cardio-kidney-metabolic conditions, general cardio-kidney-metabolic health, musculoskeletal conditions, and behavioral health. By selecting up to 10 manufacturers in each category, the agency intends to create a diverse ecosystem of validated digital health tools that CMS can confidently cover under its payment models.
Implications: The Macro View of Digital Health
The implications of Cadence’s inclusion in the TEMPO pilot extend far beyond a single company or condition.
1. The Transformation of Primary Care
Physicians are currently overwhelmed by the administrative burden of chronic disease management. By offloading the routine aspects of blood pressure titration to a FDA-vetted, AI-supported system, providers can reclaim time to focus on complex diagnostic decisions and patient relationships. This model suggests a future where the "clinic" is no longer a physical space but a distributed, digital network of care.
2. Standardization of Digital Evidence
For years, the digital health industry has been criticized for a lack of rigorous, peer-reviewed evidence. The TEMPO pilot forces companies to adhere to a higher standard of data collection. By participating in this program, Cadence is essentially building a "gold standard" template for how digital therapeutics (DTx) should report outcomes, ensuring that health systems and payers can make evidence-based decisions when choosing which software to integrate into their care pathways.
3. Medicare’s Evolving Role
CMS is signaling that it is ready to pay for digital outcomes. The alignment between the FDA’s TEMPO pilot and the new CMS innovation model is the "missing link" that has previously hindered the widespread adoption of digital health. Historically, many digital tools were orphaned because they lacked a clear reimbursement pathway. The TEMPO pilot provides the regulatory legitimacy required for these tools to become standard, billable components of the Medicare benefit.
4. Safety and Regulatory Precedent
The stringent eligibility criteria set by Cadence—specifically the exclusion of complex patients—demonstrates a maturing industry. Rather than claiming that AI can solve every medical challenge, the company is demonstrating that AI is most effective when it handles the "manageable" tasks, allowing human experts to intervene where they are most needed. This conservative, safety-first approach is likely to win the trust of clinicians and patient advocacy groups, which is essential for the long-term success of digital health.
Conclusion: A New Era of Proactive Care
As the FDA continues to fill its quota for the TEMPO pilot, the inclusion of Cadence stands as a testament to the maturation of the digital health sector. We are moving away from the era of "novelty apps" and into an era of "clinical infrastructure."
By proving that AI can manage the subtle, granular changes in a patient’s blood pressure over months rather than minutes, Cadence is providing a blueprint for the future of chronic care. If this pilot succeeds, the result will not just be better blood pressure control for thousands of patients—it will be a scalable model for managing the entire spectrum of chronic disease in an aging global population. The integration of technology and clinical judgment, backed by the rigorous oversight of the FDA, marks the beginning of a truly modern healthcare system.
